研究领域

化学生物学和药物化学。在化学生物学方面，我们集中于设计并合成新颖的针对蛋白激酶（Protein Kinase）和表观遗传蛋白（Epigenetic Enzyme）的小分子抑制剂，并运用这些功能小分子为工具，发现和解决信号传导通路、神经生物学和癌症中的新问题。在药物化学方面，以化学生物学研究成果为基础，结合传统的药物化学手段（构效关系研究、药代动力学和毒理学研究）进一步优化小分子工具化合物，以期发展针对癌症等相关疾病的“靶向治疗”药物。

学习经历

2001年，皇冠化学系化学专业，获理学学士学位；
2006年，中科院上海有机化学研究所有机化学专业，获理学博士学位；

工作经历

2006年至2011年，哈佛皇冠Dana-Farber癌症研究所,博士后研究；
2011年10月起，为皇冠生命科学学院“闽江学者”特聘教授，微生物药物课题组学科带头人；
2020年，获国家杰出青年科学基金资助。

代表性成果

(¶Co-first authorship, *Corresponding and co-corresponding author)
1. Ma, T.; Tian, X.; Zhang, B.; Li, M.; Wang, Y.; Yang, C.; Wu, J.; Wei, X.; Qu, Q.; Yu, Y.; Long, S.; Feng, J.-W.; Li, C.; Zhang, C.; Xie, C.; Wu, Y.; Xu, Z.; Chen, J.; Yu, Y.; Huang, X.; He, Y.; Yao, L.; Zhang, L.; Zhu, M.; Wang, W.; Wang, Z.-C.; Zhang, M.; Bao, Y.; Jia, W.; Lin, S.-Y.; Ye, Z.; Piao, H.-L.; Deng, X. *; Zhang, C.-S. *; Lin, S.-C. *, Low-dose metformin targets the lysosomal AMPK pathway through PEN2. Nature 2022, 603 (7899), 159-165. (Recommended by Faculty Opinions rated as exceptional) .
2. Yin, C.; Zhu, B.; Zhang, T.; Liu, T.; Chen, S.; Liu, Y.; Li, X.; Miao, X.; Li, S.; Mi, X.; Zhang, J.; Li, L.; Wei, G.; Xu, Z.; Gao, X.; Huang, C.; Wei, Z.; Goding, C. R.; Wang, P.*; Deng, X.*; Cui, R.* Pharmacological targeting of STK19 inhibits oncogenic NRAS driven melanomagenesis. Cell, 2019, 176, 1113-1127.e16. (Highlighted by Cancer Discovery) .
3. Fan, F.; He, Z.; Kong, L. L.; Chen, Q.; Yuan, Q.; Zhang, S.; Ye, J.; Liu, H.; Sun, X.; Geng, J.; Yuan, L.; Hong, L.; Xiao, C.; Zhang, W.; Li, Y.; Wang, P.; Huang, L.; Wu, X.; Ji, Z.; Wu, Q.; Xia, N. S.; Gray, N. S.; Chen, L.; Yun, C. H.*; Deng, X.*; Zhou, D.* Pharmacological targeting of kinases MST1 and MST2 augments tissue repair and regeneration. Sci. Transl. Med. 2016, 8, 352ra108. (Cover story, Highlighted by Nature Reviews Gastroenterology & Hepatology)
4. Lu, Y.; Fan, Z.; Zhu, S. J.; Huang, X.; Zhuang, Z.; Li, Y.; Deng, Z.; Gao, L.; Hong, X.; Zhang, T.; Li, L.; Sun, X.; Huang, W.; Zhang, J.; Liu, Y.; Zhang, B.; Jiang, J.; Gui, F.; Wang, Z.; Li, Q.; Song, S.; Huang, X.; Wu, Q.; Chen, L.; Zhou, D.; Zhang, J.*; Yun, C. H.*; Chen, L.*; Deng, X.*, A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLC. EMBO Mol. Med. 2022, 14 (1), e14296. (Highlighted by ALK Positive Org.) .
5. Zhang, J.*; Bhuiyan, M. I. H.; Zhang, T.; Karimy, J. K.; Wu, Z.; Fiesler, V. M.; Zhang, J.; Huang, H.; Hasan, M. N.; Skrzypiec, A. E.; Mucha, M.; Duran, D.; Huang, W.; Pawlak, R.; Foley, L. M.; Hitchens, T. K.; Minnigh, M. B.; Poloyac, S. M.; Alper, S. L.; Molyneaux, B. J.; Trevelyan, A. J.; Kahle, K. T.*; Sun, D.*; Deng, X.*, Modulation of brain cation-Cl− cotransport via the SPAK kinase inhibitor ZT-1a. Nat. Commun. , 2020, 11, 78. (Highlighted by The Medical News) .
6. Wang, Y.; Zhang, L.; Wei, Y.; Huang, W.; Li, L.; Wu, A. A.; Dastur, A.; Greninger, P.; Bray, W. M.; Zhang, C. S.; Li, M.; Lian, W.; Hu, Z.; Wang, X.; Liu, G.; Yao, L.; Guh, J. H.; Chen, L.; Wang, H. R.; Zhou, D.; Lin, S. C.; Xu, Q.; Shen, Y.; Zhang, J.; Jurica, M. S.; Benes, C. H.; Deng, X.*, Pharmacological Targeting of Vacuolar H(+)-ATPase via Subunit V1G Combats Multidrug-Resistant Cancer. Cell Chem. Biol. 2020, 27 (11), 1359-1370.e8.
7. Li, Y.; Liu, Z.; Li, L.; Lian, W.; He, Y.; Khalil, E.; Mäkilä, E.; Zhang, W.; Torrieri, G.; Liu, X.; Su, J.; Xiu, Y.; Fontana, F.; Salonen, J.; Hirvonen, J.; Liu, W.; Zhang, H.*; Santos, H. A.*; Deng, X.*, Tandem-Mass-Tag Based Proteomic Analysis Facilitates Analyzing Critical Factors of Porous Silicon Nanoparticles in Determining Their Biological Responses under Diseased Condition. Adv. Science 2020, 7 (15), 2001129.
8. Zhang, L.; Wang, Y.; Huang, W.; Wei, Y.; Jiang, Z.; Kong, L.; Wu, A. A.; Hu, Z.; Huang, H.; Xu, Q.; Li, L.; Deng, X.*, Biosynthesis and Chemical Diversification of Verucopeptin Leads to Structural and Functional Versatility. Org. Letters 2020, 22 (11), 4366-4371.
9. Gui, F.; Jiang, J.; He, Z.; Li, L.; Li, Y.; Deng, Z.; Lu, Y.; Wu, X.; Chen, G.; Su, J.; Song, S.; Zhang, Y. M.; Yun, C. H.; Huang, X.; Weisberg, E.; Zhang, J.*; Deng, X.*, A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk(C481S) mutation in B-cell malignancies. Br. J. Pharmacol. 2019, 176, 4491-4509.
10. Tian, M.; Zeng, T.; Liu, M.; Han, S.; Lin, H.; Lin, Q.; Li, L.; Jiang, T.; Li, G.; Zhang, T.; Kang, Q.; Deng, X.*; Wang, H. R.*, A cell-based high-throughput screening method based on a ubiquitin-reference technique for identifying modulators of E3 ligases. J. Biol. Chem. 2019, 294 (8), 2880-2891.
11. Liu, Z.; Li, Y.; Li, W.; Lian, W.; Kemell, M.; Hietala, S.; Figueiredo, P.; Li, L.; Mäkilä, E.; Ma, M.; Salonen, J.; Hirvonen, J. T.; Liu, D.; Zhang, H.*; Deng, X.*; Santos, H. A.*, Close-loop dynamic nanohybrids on collagen-ark with in situ gelling transformation capability for biomimetic stage-specific diabetic wound healing. Materials Horizons 2019, 6, 385-393.
12. Huang, W.; Sun, X.; Li, Y.; He, Z.; Li, L.; Deng, Z.; Huang, X.; Han, S.; Zhang, T.; Zhong, J.; Wang, Z.; Xu, Q.; Zhang, J.; Deng, X.* Discovery and Identification of Small Molecules as Methuosis Inducers with in Vivo Antitumor Activities. J. Med. Chem. 2018, 61, 5424-5434.
13. Liu, Z.; Li, Y.; Li, W.; Xiao, C.; Liu, D.; Dong, C.; Zhang, M.; Mäkilä, E.; Kemell, M.; Salonen, J.; Hirvonen, J. T.; Zhang, H.*; Zhou, D.*; Deng, X.*; Santos, H. A.* Multifunctional Nanohybrid Based on Porous Silicon Nanoparticles, Gold Nanoparticles, and Acetalated Dextran for Liver Regeneration and Acute Liver Failure Theranostics. Adv. Materials 2018, 30, e1703393.
14. Ning, N.; Yu, Y.; Wu, M.; Zhang, R.; Zhang, T.; Zhu, C.; Huang, L.; Yun, C. H.; Benes, C. H.; Zhang, J.; Deng, X.*; Chen, Q.*; Ren, R.*, A Novel Microtubule Inhibitor Overcomes Multidrug Resistance in Tumors. Cancer Res. 2018, 78, 5949-5957.
15. Jiang, J.; Gui, F.; He, Z.; Li, L.; Li, Y.; Li, S.; Wu, X.; Deng, Z.; Sun, X.; Huang, X.; Huang, W.; Han, S.; Zhang, T.; Wang, Z.; Jiao, B.; Song, S.; Wang, H.-R.; Chen, L.; Zhou, D.; Liu, Q.; Ren, R.*; Zhang, J.*; Deng, X.* Targeting BRK-positive breast cancers with small molecule kinase inhibitors Cancer Res. 2017, 77, 175-186. (Highlighted by BioWorld™️) .
16. Jiang, H.; He, H.; Chen, Y.; Huang, W.; Cheng, J.; Ye, J.; Wang, A.; Tao, J.; Wang, C.; Liu, Q.; Jin, T.; Jiang, W.*; Deng, X.*; Zhou, R.* Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J. Exp. Med. 2017, 214, 3219-3238. (Highlighted by Nature Reviews Rheumatology) .
17. He, H.; Jiang, H.; Chen, Y.; Ye, J.; Wang, A.; Wang, C.; Liu, Q.; Liang, G.; Deng, X.*; Jiang, W.*; Zhou, R.* Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nat. Commun. 2018, 9, 2550.
18. Wang, Y.; Qi, S.; Zhan, Y.; Zhang, N.; Wu, A.; Gui, F.; Guo, K.; Yang, Y.; Hu, Z.; Zheng, Z.; Song, S.; Xu, Q.; Shen, Y.*; Deng, X.* Aspertetranones A-D, Meroterpenoids from the Marine Algal-associated Fungus Aspergillus sp. J. Nat. Prod. 2015, 78, 2405-10.
19. Deng, X. ¶; Dzamko, N. ¶; Prescott, A.; Davies, P.; Liu, Q.; Yang, Q.; Lee, J. D.; Patricelli, M. P.; Nomanbhoy, T. K.; Alessi, D. R.; Gray, N. S. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat. Chem. Biol. 2011, 7, 203-5.
20. Yang, Q. ¶; Deng, X. ¶; Lu, B. ¶; Cameron, M.; Fearns, C.; Patricelli, M. P.; Yates, J. R., 3rd; Gray, N. S.; Lee, J. D. Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell 2010, 18, 258-67.

获奖及荣誉

1.2017年，获福建省第十四届“青年科技奖”
2.2018年，获“药明康德生命化学研究奖”学者奖
3.2019年，获皇冠“田昭武学科交叉奖”（特等奖）
4.2019年，获福建省自然科学奖一等奖（第三完成人）